Untitled
General and Local Anesthetic Pharmacology
Classification of General Anesthetics:
- Intravenous Anesthetics: Includes Propofol, Tiopental (Thiopental), Etomidate, Ketamina (Ketamine), and Midazolam.
- Inhaled Anesthetics: Includes Podtlenek azotu (Nitrous oxide), Sewofluran (Sevoflurane), and Eter (Ether).
Intravenous Anesthetic Profiles:
- Propofol: An intravenous general anesthetic characterized by a rapid onset of action and exceptionally fast recovery/awakening potential.
- Ketamina (Ketamine): An intravenous agent strictly contraindicated in craniocerebral injuries (urazy czaszkowo-mózgowe) because it increases intracranial pressure. It is specifically indicated for patients with impending or severe hypotension due to its hemodynamic effect of elevating arterial blood pressure.
- Tiopental (Thiopental), Etomidate, and Midazolam: Represent key intravenous sedative/anesthetic agents with distinct onset and recovery kinetics.
Local Anesthetics (Środki miejscowo znieczulające):
- Representative Agents: Includes Lidokaina (Lidocaine), Bupiwakaina (Bupivacaine), Kokaina (Cocaine), and Benzokaina (Benzocaine).
- Mechanism of Action: Local anesthetics act by blocking voltage-gated sodium channels (kanały sodowe), preventing the influx of sodium ions required for neuronal depolarization and signal conduction.
- Systemic Toxicity of Intravenous Local Anesthetics: When agents such as Lidokaina (Lidocaine) enter the systemic circulation or are administered intravenously, they can induce dangerous cardiotoxic and neurotoxic adverse effects, including:
- Całkowity blok serca (Complete heart block)
- Bradykardia (Bradycardia)
- Hipotensja (Hypotension)
- Depresja OUN (Central Nervous System depression)
- Benzokaina (Benzocaine): A specialized topical local anesthetic utilized in:
- Throat lozenges (tabletki do ssania) to relieve sore throat pain
- Powders or ointments (proszki do pokrywania bolesnych owrzodzeń skóry) for painful cutaneous ulcers
- Condoms (prezerwatywy) to delay ejaculation
- Vasoconstrictive Adjuvants: Vasoconstrictive agents, primarily Adrenalina (Adrenaline/Epinephrine), are added to local anesthetic solutions to induce localized vasoconstriction, reduce systemic absorption, minimize local surgical bleeding, and extend the overall duration of the anesthetic effect.
Analgesic Pharmacology, Opioids, NSAIDs, and Toxicity Antidotes
Opioid Analgesics and Clinical Pharmacodynamics:
- Representative Opioid Drugs: Morfina (Morphine), Petydyna (Pethidine), Fentanyl, and Metadon (Methadone).
- Pharmacological Spectrum of Morfina (Morphine):
- Analgezja (Analgesia)
- Depresja oddechowa (Respiratory depression)
- Zmniejszenie perystaltyki przewodu pokarmowego (Decreased gastrointestinal motility, leading to constipation)
- Nudności i wymioty (Nausea and vomiting via chemoreceptor trigger zone stimulation)
- Clinical Manifestations of Opioid Toxicity/Poisoning:
- Szpilkowate źrenice (Pinpoint/miotic pupils)
- Euforia (Euphoria) and potential respiratory depression
- Antidote for Opioid Overdose: Nalokson (Naloxone) is the specific competitive opioid receptor antagonist used to reverse opioid toxicity.
- Prophylaxis against Opioid Adverse Effects:
- Antiemetic drugs (leki przeciwwymiotne) during the initial days of therapy to control nausea
- Laxatives (leki przeczyszczające) administered continuously throughout the entire duration of opioid therapy to prevent and manage severe constipation
Nonsteroidal Anti-Inflammatory Drugs (NSLPZ / NSAIDs) and Non-Opioid Analgesics:
- Mechanism of Action: NSLPZ inhibit cyclooxygenase enzymes, specifically both and .
- Prophylaxis against NSLPZ Adverse Effects: Proton Pump Inhibitors (IPP / PPIs) are routinely administered alongside NSLPZ therapy to prevent gastrointestinal mucosal ulceration and bleeding.
- Metmizol (Metamizole / Dipyrone): Carries a distinct risk of severe myelosuppression, manifesting as agranulocytosis and pancytopenia.
- Antidote for Paracetamol Toxicity: Acetylocysteina (Acetylcysteine / N-acetylcysteine) is administered in Paracetamol overdose to replenish hepatic glutathione stores.
Antidote and Overdose Management Summary:
- Opioid Poisoning: Nalokson (Naloxone)
- Paracetamol Poisoning: Acetylocysteina (Acetylcysteine)
- Benzodiazepine Poisoning: Flumazenil
- Additional reference compounds mentioned in overdose context: Glukagon (Glucagon), Kobalamina (Cobalamin)
Therapeutic Pain Management Protocols:
- Musculoskeletal Pain (Ból mięśniowo-szkieletowy): Paracetamol is the first-line choice of treatment.
- Colicky Pain (Ból kolkowy): Spasmolytic/antispasmodic agents, specifically Hioscyna (Hyoscine) and Drotaweryna (Drotaverine), are first-line therapies.
- Neuropathic Pain (Ból o charakterze neuropatycznym): First-line interventions include Pregabalina (Pregabalin), Gabapentyna (Gabapentin), Amitryptylina (Amitriptyline), and Duloksetyna (Duloxetine).
- Oncological / Cancer Pain (Ból u pacjenta chorego nowotworowo): Morfina (Morphine) is the primary first-line opioid analgesic.
Anxiolytic, Hypnotic, and Anticonvulsant Pharmacology
Anxiolytics and Hypnotics:
- Combined Anxiolytic and Hypnotic Actions: Lorazepam exhibits both pronounced anxiolytic (przeciwlękowe) and hypnotic (nasenne) properties.
- Broad Anxiolytic Agents: Anxiolytic properties are shared across multiple drug classes, including Fluoksetyna (Fluoxetine), Wenlaflaksyna (Venlafaxine), Gabapentyna (Gabapentin), and Olanzapina (Olanzapine).
- Hypnotic Non-Benzodiazepines: Zopiklon (Zopiclone) and Zolpidem.
- Anxiolytic Non-Benzodiazepines: Buspiron (Buspirone) and Paroksetyna (Paroxetine).
Benzodiazepines:
- Mechanism of Action: Benzodiazepines bind to and activate/modulate the receptor complex.
- Clinical Effects:
- Zmniejszenie lęku (Anxiolysis / Anxiety reduction)
- Działanie nasenne (Hypnotic / Sedative effect)
- Zmniejszenie napięcia mięśniowego (Muscle relaxation)
- Działanie przeciwdrgawkowe (Anticonvulsant effect)
- Specific Antidote: Flumazenil acts as a specific competitive antagonist for benzodiazepine overdose (e.g., Diazepam toxicity).
Anticonvulsant (Antiepileptic) Pharmacotherapy:
- Agents with Anticonvulsant Potential: Karbamazepina (Carbamazepine), Kwas walproinowy (Valproic acid), Diazepam, and Gabapentyna (Gabapentin).
- Generalized Epileptic Seizures (Uogólnione napady padaczkowe): Kwas walproinowy (Valproic acid) and Lamotrygina (Lamotrigine) are indicated first-line treatments. Fenytoina (Phenytoin) and Karbamazepina (Carbamazepine) represent additional antiepileptics used in targeted seizure disorders.
Antipsychotic (Neuroleptic) Pharmacotherapy
First-Generation (Typical) Antipsychotics:
- Representative Agents: Chlorpromazyna (Chlorpromazine) and Haloperidol.
- Mechanism & Side Effects: High-affinity antagonism of dopamine receptors. Blokade of receptors causes severe motor disturbances, including acute dystonias (ostre dystonie) and tardive dyskinesias (późne dyskinezje), alongside hyperprolactinemia due to increased prolactin secretion.
- Haloperidol: Strongly associated with extrapyramidal motor disorders and elevated prolactin levels via blockade.
Second-Generation (Atypical) Antipsychotics:
- Representative Agents: Klozapina (Clozapine), Arypiprazol (Aripiprazole), Risperidon (Risperidone), Olanzapina (Olanzapine), and Kwetiapina (Quetiapine).
- Klozapina (Clozapine):
- Demonstrates high therapeutic efficacy in treatment-resistant schizophrenia (schizofrenia oporna na pierwszą linię leczenia).
- Carries a significant risk of agranulocytosis (ryzyko wystąpienia agranulocytozy), requiring strict blood count monitoring.
- Notably does not induce motor/extrapyramidal adverse effects.
- Arypiprazol (Aripiprazole):
- Preferred as first-line long-term therapy in obese patients with schizophrenia (utyły pacjent chorujący na schizofrenię w terapii przewlekłej) due to its minimal metabolic impact and low risk of weight gain compared to Olanzapina or Klozapina.
Antidepressant Pharmacotherapy, Mood Stabilizers, and Addiction Treatments
Antidepressant Classes and Pharmacodynamics:
- Onset of Therapeutic Effect: Clinical response and antidepressant efficacy become evident after 2 weeks of continuous therapy (po 2 tygodniach terapii).
- Selective Serotonin Reuptake Inhibitors (SSRI):
- Members include Fluoksetyna (Fluoxetine), Sertralina (Sertralina), Citalopram, and Escitalopram.
- Note: Wenlaflaksyna (Venlafaxine) is not an SSRI.
- SSRI Adverse Effects: Nausea (nudności), insomnia (bezsenność), loss of libido (utrata libido), and life-threatening Serotonin Reaction/Syndrome (reakcja serotoninowa) when co-administered with MAOIs.
- Serotonin and Norepinephrine Reuptake Inhibitors (SNRI):
- Includes Duloksetyna (Duloxetine) and Wenlaflaksyna (Venlafaxine).
- Norepinephrine and Dopamine Reuptake Inhibitors (NDRI / NRI):
- Includes Bupropion.
- Tricyclic Antidepressants (TLPD / TCA):
- Includes Imipramina (Imipramine), Amitryptylina (Amitriptyline), Nortryptylina (Nortriptyline), and Klomipramina (Clomipramine).
- Monoamine Receptor Antagonists:
- Includes Mirtazapina (Mirtazapine), Trazodon (Trazodone), and Mianseryna (Mianserin).
- Note: Moklebemid (Moclobemide) is a monoamine oxidase inhibitor, not a monoamine receptor antagonist.
- Monoamine Oxidase Inhibitors (MAOI):
- Characterized by the potential to induce the dangerous "cheese reaction" (reakcja serowa), a severe hypertensive crisis triggered by tyramine accumulation when combined with certain foods.
**